| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.724 | 0.005 | 0.726 | Anticonvulsant | 0.726 0.005 DBMET00281 0.523 0.011 DBMET00743 0.525 0.011 DBMET03601 | DBMET00281 | |
| 0.541 | 0.002 | 0.541 | Benzodiazepine agonist | 0.342 0.003 DBMET00281 0.251 0.004 DBMET00743 0.161 0.006 DBMET03601 | ||
| 0.535 | 0.018 | 0.559 | GABA C receptor rho-3 antagonist | 0.46 0.038 DBMET00281 0.559 0.013 DBMET00743 0.488 0.029 DBMET03601 | DBMET00743 | |
| 0.476 | 0.034 | 0.476 | Thioredoxin glutathione reductase inhibitor | 0.462 0.037 DBMET00281 0.434 0.045 DBMET00743 0.423 0.048 DBMET03601 | ||
| 0.433 | 0.042 | 0.637 | Aldehyde oxidase inhibitor | 0.448 0.04 DBMET00281 0.63 0.015 DBMET00743 0.637 0.014 DBMET03601 | DBMET03601 | |
| 0.395 | 0.023 | 0.395 | Psychostimulant | 0.313 0.039 DBMET00281 0.376 0.027 DBMET00743 0.292 0.045 DBMET03601 | ||
| 0.407 | 0.037 | 0.407 | Nootropic | 0.274 0.089 DBMET00281 0.28 0.085 DBMET00743 0.186 0.178 DBMET03601 | ||
| 0.37 | 0.005 | 0.37 | GABA receptor agonist | 0.249 0.01 DBMET00281 0.298 0.006 DBMET00743 0.197 0.018 DBMET03601 | ||
| 0.335 | 0.033 | 0.335 | Sigma receptor agonist | 0.312 0.037 DBMET00743 | ||
| 0.317 | 0.023 | 0.317 | Gastrin inhibitor | 0.287 0.042 DBMET00281 0.273 0.055 DBMET00743 0.237 0.096 DBMET03601 | ||
| 0.394 | 0.106 | 0.453 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.453 0.059 DBMET00281 0.268 0.259 DBMET00743 0.332 0.172 DBMET03601 | DBMET00281 | |
| 0.369 | 0.089 | 0.489 | 15-Lipoxygenase inhibitor | 0.357 0.096 DBMET00281 0.489 0.043 DBMET00743 0.474 0.047 DBMET03601 | DBMET00743 | |
| 0.324 | 0.083 | 0.334 | Thyroid hormone antagonist | 0.28 0.105 DBMET00281 0.334 0.079 DBMET00743 0.288 0.1 DBMET03601 | DBMET00743 | |
| 0.285 | 0.053 | 0.285 | 5 Hydroxytryptamine uptake stimulant | 0.258 0.074 DBMET00281 0.277 0.058 DBMET00743 0.25 0.08 DBMET03601 | ||
| 0.222 | 0.004 | 0.229 | Nociceptin (N/OFQ) receptor antagonist | 0.229 0.004 DBMET00281 0.155 0.004 DBMET00743 0.162 0.004 DBMET03601 | DBMET00281 | |
| 0.238 | 0.028 | 0.238 | Polo-like kinase-3 inhibitor | 0.192 0.05 DBMET00743 | ||
| 0.258 | 0.06 | 0.327 | Cyclic AMP phosphodiesterase inhibitor | 0.318 0.035 DBMET00281 0.269 0.055 DBMET00743 0.327 0.032 DBMET03601 | DBMET03601 | |
| 0.197 | 0.005 | 0.197 | Acetylcholine release stimulant | 0.13 0.034 DBMET00281 0.153 0.015 DBMET00743 0.1 0.088 DBMET03601 | ||
| 0.221 | 0.038 | 0.221 | Cytidine deaminase inhibitor | 0.165 0.065 DBMET00743 | ||
| 0.192 | 0.017 | 0.216 | 5 Hydroxytryptamine 3A agonist | 0.216 0.011 DBMET00281 0.172 0.025 DBMET00743 0.197 0.016 DBMET03601 | DBMET00281 | |
| 0.234 | 0.061 | 0.267 | RNA-directed DNA polymerase inhibitor | 0.249 0.05 DBMET00281 0.25 0.049 DBMET00743 0.267 0.041 DBMET03601 | DBMET03601 | |
| 0.213 | 0.04 | 0.237 | Diuretic | 0.237 0.033 DBMET00281 0.185 0.051 DBMET00743 0.206 0.042 DBMET03601 | DBMET00281 | |
| 0.23 | 0.059 | 0.249 | Anesthetic general | 0.193 0.078 DBMET00281 0.249 0.051 DBMET00743 0.214 0.067 DBMET03601 | DBMET00743 | |
| 0.279 | 0.114 | 0.324 | Calcium channel activator | 0.324 0.069 DBMET00281 0.261 0.134 DBMET00743 0.308 0.084 DBMET03601 | DBMET00281 | |
| 0.165 | 0.005 | 0.165 | Cholecystokinin A antagonist | 0.075 0.013 DBMET00281 0.093 0.01 DBMET00743 0.036 0.027 DBMET03601 | ||
| 0.163 | 0.005 | 0.163 | Bromodomain-containing protein 2 inhibitor | 0.146 0.01 DBMET00281 0.133 0.015 DBMET00743 0.113 0.028 DBMET03601 | ||
| 0.312 | 0.156 | 0.339 | DNA directed DNA polymerase inhibitor | 0.272 0.178 DBMET00281 0.339 0.143 DBMET00743 0.295 0.164 DBMET03601 | DBMET00743 | |
| 0.163 | 0.008 | 0.163 | 5 Hydroxytryptamine 3 antagonist | 0.064 0.032 DBMET00281 0.058 0.037 DBMET00743 | ||
| 0.312 | 0.159 | 0.325 | DNA polymerase beta inhibitor | 0.282 0.175 DBMET00281 0.325 0.152 DBMET00743 0.296 0.167 DBMET03601 | DBMET00743 | |
| 0.283 | 0.133 | 0.459 | Histamine release inhibitor | 0.406 0.073 DBMET00281 0.373 0.089 DBMET00743 0.459 0.046 DBMET03601 | DBMET03601 | |
| 0.186 | 0.038 | 0.186 | GABA C receptor rho-2 antagonist | 0.169 0.052 DBMET00281 0.178 0.044 DBMET00743 0.161 0.06 DBMET03601 | ||
| 0.198 | 0.05 | 0.288 | Heat shock protein 90 alpha antagonist | 0.213 0.042 DBMET00281 0.272 0.02 DBMET00743 0.288 0.017 DBMET03601 | DBMET03601 | |
| 0.236 | 0.09 | 0.25 | 5 Hydroxytryptamine 1E antagonist | 0.25 0.075 DBMET00281 0.226 0.102 DBMET00743 0.241 0.085 DBMET03601 | DBMET00281 | |
| 0.192 | 0.046 | 0.192 | Acetylcholine M1 receptor antagonist | 0.171 0.058 DBMET00281 0.187 0.048 DBMET00743 0.168 0.06 DBMET03601 | ||
| 0.168 | 0.028 | 0.169 | Pregnane X receptor agonist | 0.169 0.027 DBMET00281 0.16 0.038 DBMET00743 0.16 0.037 DBMET03601 | DBMET00281 | |
| 0.144 | 0.005 | 0.144 | Cholecystokinin antagonist | 0.064 0.016 DBMET00281 0.073 0.013 DBMET00743 | ||
| 0.154 | 0.021 | 0.192 | Androgen antagonist | 0.135 0.027 DBMET00281 0.192 0.014 DBMET00743 0.172 0.017 DBMET03601 | DBMET00743 | |
| 0.135 | 0.005 | 0.135 | Purinergic P2X antagonist | 0.131 0.005 DBMET00281 0.075 0.015 DBMET00743 0.074 0.016 DBMET03601 | ||
| 0.275 | 0.145 | 0.275 | Beta lactamase inhibitor | 0.195 0.189 DBMET00281 | ||
| 0.168 | 0.04 | 0.38 | Glutamate receptor antagonist | 0.38 0.005 DBMET00281 0.161 0.044 DBMET00743 0.331 0.008 DBMET03601 | DBMET00281 | |
| 0.135 | 0.012 | 0.135 | Purinergic P2 antagonist | 0.129 0.013 DBMET00281 0.082 0.031 DBMET00743 0.078 0.034 DBMET03601 | ||
| 0.143 | 0.023 | 0.158 | Acetylcholine M3 receptor agonist | 0.158 0.015 DBMET00281 0.088 0.053 DBMET00743 0.115 0.037 DBMET03601 | DBMET00281 | |
| 0.261 | 0.142 | 0.261 | Calpain 2 inhibitor | 0.22 0.171 DBMET00281 0.197 0.19 DBMET00743 | ||
| 0.221 | 0.105 | 0.225 | 5 Hydroxytryptamine release stimulant | 0.223 0.104 DBMET00281 0.223 0.104 DBMET00743 0.225 0.103 DBMET03601 | DBMET03601 | |
| 0.139 | 0.024 | 0.139 | Electrolyte absorption antagonist | 0.12 0.036 DBMET00281 0.11 0.046 DBMET00743 0.094 0.066 DBMET03601 | ||
| 0.17 | 0.055 | 0.293 | Heat shock protein 90 antagonist | 0.206 0.035 DBMET00281 0.256 0.019 DBMET00743 0.293 0.011 DBMET03601 | DBMET03601 | |
| 0.117 | 0.004 | 0.117 | Corticotropin releasing factor 2 receptor antagonist | 0.109 0.005 DBMET00281 0.079 0.018 DBMET00743 0.074 0.024 DBMET03601 | ||
| 0.141 | 0.029 | 0.141 | Acetylcholine agonist | 0.126 0.034 DBMET00281 | ||
| 0.119 | 0.011 | 0.119 | Acetylcholine M5 receptor agonist | 0.104 0.018 DBMET00281 0.073 0.04 DBMET00743 | ||
| 0.214 | 0.108 | 0.214 | Interleukin agonist | 0.201 0.12 DBMET00281 0.204 0.117 DBMET00743 0.19 0.13 DBMET03601 | ||
| 0.109 | 0.004 | 0.472 | Purinergic P2X4 antagonist | 0.438 0.002 DBMET00281 0.123 0.004 DBMET00743 0.472 0.002 DBMET03601 | DBMET03601 | |
| 0.116 | 0.013 | 0.116 | GABA A receptor antagonist | 0.093 0.018 DBMET00281 0.088 0.019 DBMET00743 0.069 0.026 DBMET03601 | ||
| 0.169 | 0.073 | 0.18 | ATPase inhibitor | 0.175 0.064 DBMET00281 0.173 0.066 DBMET00743 0.18 0.058 DBMET03601 | DBMET03601 | |
| 0.208 | 0.113 | 0.236 | Spasmolytic | 0.187 0.131 DBMET00281 0.236 0.097 DBMET00743 0.208 0.113 DBMET03601 | DBMET00743 | |
| 0.108 | 0.014 | 0.108 | GABA receptor antagonist | 0.09 0.018 DBMET00281 0.084 0.02 DBMET00743 0.071 0.025 DBMET03601 | ||
| 0.146 | 0.054 | 0.146 | Ca2+-transporting ATPase inhibitor | 0.137 0.085 DBMET00281 0.145 0.056 DBMET00743 0.136 0.089 DBMET03601 | ||
| 0.113 | 0.022 | 0.164 | Glycine receptor antagonist | 0.164 0.005 DBMET00281 0.092 0.041 DBMET00743 0.142 0.009 DBMET03601 | DBMET00281 | |
| 0.098 | 0.008 | 0.119 | MDM2 inhibitor | 0.119 0.004 DBMET00281 0.081 0.018 DBMET00743 0.103 0.006 DBMET03601 | DBMET00281 | |
| 0.152 | 0.063 | 0.152 | Mannose-6-phosphate isomerase inhibitor | 0.135 0.08 DBMET00281 0.143 0.07 DBMET00743 0.128 0.089 DBMET03601 | ||
| 0.116 | 0.032 | 0.116 | Polo-like kinase-1 inhibitor | 0.092 0.059 DBMET00743 | ||
| 0.097 | 0.016 | 0.143 | Phospholipase D inhibitor | 0.143 0.004 DBMET00281 0.076 0.042 DBMET00743 0.123 0.005 DBMET03601 | DBMET00281 | |
| 0.115 | 0.034 | 0.115 | Histamine N-methyltransferase inhibitor | 0.105 0.041 DBMET00281 0.106 0.041 DBMET00743 0.096 0.05 DBMET03601 | ||
| 0.105 | 0.024 | 0.107 | Acetylcholine M4 receptor antagonist | 0.107 0.024 DBMET00281 | DBMET00281 | |
| 0.097 | 0.016 | 0.097 | 5 Hydroxytryptamine 3 agonist | 0.071 0.034 DBMET00281 0.074 0.031 DBMET00743 | ||
| 0.219 | 0.139 | 0.219 | Thyroid hormone beta antagonist | 0.18 0.173 DBMET00281 0.217 0.141 DBMET00743 0.179 0.175 DBMET03601 | ||
| 0.093 | 0.015 | 0.093 | MAP kinase 7 inhibitor | 0.082 0.038 DBMET00743 | ||
| 0.181 | 0.104 | 0.202 | 5 Hydroxytryptamine 3E antagonist | 0.202 0.059 DBMET00281 | DBMET00281 | |
| 0.1 | 0.025 | 0.1 | Polo-like kinase-2 inhibitor | 0.074 0.049 DBMET00743 | ||
| 0.121 | 0.047 | 0.121 | Multidrug resistance-associated protein 1 inhibitor | 0.108 0.065 DBMET00281 0.119 0.05 DBMET00743 0.108 0.065 DBMET03601 | ||
| 0.081 | 0.007 | 0.081 | 5 Hydroxytryptamine 3B antagonist | 0.037 0.024 DBMET00281 0.036 0.025 DBMET00743 | ||
| 0.078 | 0.005 | 0.084 | Parathyroid hormone antagonist | 0.084 0.004 DBMET00281 0.066 0.008 DBMET00743 0.072 0.006 DBMET03601 | DBMET00281 | |
| 0.283 | 0.213 | 0.403 | Caspase 9 stimulant | 0.333 0.16 DBMET00281 0.343 0.151 DBMET00743 0.403 0.109 DBMET03601 | DBMET03601 | |
| 0.074 | 0.004 | 0.108 | Nociceptin (N/OFQ) receptor agonist | 0.108 0.004 DBMET00281 0.044 0.006 DBMET00743 0.068 0.005 DBMET03601 | DBMET00281 | |
| 0.075 | 0.006 | 0.075 | Cholecystokinin B antagonist | 0.032 0.02 DBMET00281 0.038 0.015 DBMET00743 | ||
| 0.218 | 0.149 | 0.304 | Cholesterol antagonist | 0.243 0.13 DBMET00281 0.282 0.103 DBMET00743 0.304 0.089 DBMET03601 | DBMET03601 | |
| 0.134 | 0.067 | 0.198 | NADPH oxidase inhibitor | 0.141 0.061 DBMET00281 0.186 0.039 DBMET00743 0.198 0.035 DBMET03601 | DBMET03601 | |
| 0.122 | 0.056 | 0.223 | Cystathionine beta-synthase inhibitor | 0.223 0.019 DBMET00743 0.161 0.036 DBMET03601 | DBMET00743 | |
| 0.269 | 0.203 | 0.433 | 5 Hydroxytryptamine release inhibitor | 0.409 0.073 DBMET00281 0.291 0.176 DBMET00743 0.433 0.059 DBMET03601 | DBMET03601 | |
| 0.2 | 0.136 | 0.257 | Tyrosine 3 hydroxylase inhibitor | 0.205 0.127 DBMET00281 0.251 0.067 DBMET00743 0.257 0.062 DBMET03601 | DBMET03601 | |
| 0.088 | 0.024 | 0.088 | 5 Hydroxytryptamine 3A antagonist | 0.061 0.055 DBMET00281 | ||
| 0.126 | 0.062 | 0.126 | 5 Hydroxytryptamine antagonist | |||
| 0.082 | 0.018 | 0.082 | Bromodomain-containing protein 4 inhibitor | 0.054 0.038 DBMET00743 | ||
| 0.118 | 0.055 | 0.126 | Ferrochelatase inhibitor | 0.126 0.05 DBMET00281 | DBMET00281 | |
| 0.119 | 0.057 | 0.119 | Sphingosine 1-phosphate receptor 2 agonist | 0.113 0.068 DBMET00743 | ||
| 0.154 | 0.097 | 0.182 | Amyloid beta precursor protein antagonist | 0.182 0.07 DBMET00743 0.147 0.105 DBMET03601 | DBMET00743 | |
| 0.163 | 0.106 | 0.163 | MAP kinase kinase 5 inhibitor | 0.161 0.113 DBMET00281 | ||
| 0.106 | 0.051 | 0.166 | Potassium channel (Ca-activated) activator | 0.11 0.047 DBMET00281 0.159 0.025 DBMET00743 0.166 0.023 DBMET03601 | DBMET03601 | |
| 0.156 | 0.101 | 0.187 | Succinate dehydrogenase inhibitor | 0.174 0.075 DBMET00281 0.168 0.084 DBMET00743 0.187 0.061 DBMET03601 | DBMET03601 | |
| 0.077 | 0.023 | 0.077 | Acetylcholine muscarinic agonist | 0.062 0.032 DBMET00281 | ||
| 0.078 | 0.025 | 0.097 | Androgen agonist | 0.077 0.025 DBMET00281 0.097 0.016 DBMET00743 0.097 0.016 DBMET03601 | DBMET03601 | |
| 0.072 | 0.02 | 0.16 | AMPA receptor antagonist | 0.16 0.005 DBMET00281 0.062 0.024 DBMET00743 0.144 0.006 DBMET03601 | DBMET00281 | |
| 0.068 | 0.019 | 0.068 | 5 Hydroxytryptamine 4 antagonist | 0.061 0.023 DBMET00281 0.05 0.038 DBMET00743 | ||
| 0.203 | 0.154 | 0.235 | Prostaglandin dehydrogenase inhibitor | 0.235 0.135 DBMET00743 0.199 0.157 DBMET03601 | DBMET00743 | |
| 0.058 | 0.014 | 0.058 | Glutamate (mGluR group III) antagonist | 0.05 0.021 DBMET00281 0.048 0.023 DBMET00743 0.042 0.035 DBMET03601 | ||
| 0.078 | 0.034 | 0.123 | Dopamine D1 antagonist | 0.062 0.047 DBMET00281 0.123 0.019 DBMET00743 0.094 0.027 DBMET03601 | DBMET00743 | |
| 0.094 | 0.051 | 0.11 | NADH dehydrogenase inhibitor | 0.102 0.042 DBMET00281 0.102 0.042 DBMET00743 0.11 0.035 DBMET03601 | DBMET03601 | |
| 0.057 | 0.016 | 0.057 | Benzodiazepine antagonist | 0.048 0.032 DBMET00281 | ||
| 0.124 | 0.082 | 0.124 | Toll-Like receptor 9 antagonist | |||
| 0.191 | 0.15 | 0.3 | Lipoxygenase inhibitor | 0.3 0.071 DBMET00743 0.213 0.127 DBMET03601 | DBMET00743 | |
| 0.085 | 0.045 | 0.085 | Nicotinic alpha4beta2 receptor antagonist | 0.074 0.057 DBMET00281 | ||
| 0.079 | 0.042 | 0.079 | Vanilloid 4 agonist | 0.071 0.062 DBMET00281 | ||
| 0.099 | 0.063 | 0.099 | GABA C receptor rho-1 antagonist | 0.096 0.067 DBMET00281 0.089 0.08 DBMET00743 0.087 0.085 DBMET03601 | ||
| 0.062 | 0.027 | 0.065 | Acetylcholine M2 receptor agonist | 0.065 0.023 DBMET00281 0.049 0.045 DBMET03601 | DBMET00281 | |
| 0.098 | 0.063 | 0.098 | Insulin receptor antagonist | 0.09 0.076 DBMET00281 | ||
| 0.047 | 0.012 | 0.047 | Acetylcholine M4 receptor agonist | 0.039 0.015 DBMET00281 | ||
| 0.057 | 0.023 | 0.057 | Bromodomain-containing protein 3 inhibitor | 0.046 0.04 DBMET00281 | ||
| 0.056 | 0.023 | 0.056 | Acetylcholine M1 receptor agonist | 0.045 0.028 DBMET00281 | ||
| 0.047 | 0.015 | 0.05 | p53 inhibitor | 0.05 0.014 DBMET00281 0.032 0.029 DBMET00743 0.034 0.026 DBMET03601 | DBMET00281 | |
| 0.161 | 0.129 | 0.22 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.194 0.103 DBMET00281 0.18 0.113 DBMET00743 0.22 0.089 DBMET03601 | DBMET03601 | |
| 0.069 | 0.037 | 0.072 | Dopamine D4 antagonist | 0.072 0.035 DBMET00281 0.051 0.049 DBMET03601 | DBMET00281 | |
| 0.071 | 0.04 | 0.071 | Glutamate (mGluR7) antagonist | 0.065 0.052 DBMET00743 | ||
| 0.081 | 0.052 | 0.081 | Glutamate receptor agonist | |||
| 0.044 | 0.015 | 0.052 | CF transmembrane conductance regulator antagonist | 0.043 0.019 DBMET00281 0.052 0.007 DBMET00743 0.05 0.009 DBMET03601 | DBMET00743 | |
| 0.092 | 0.063 | 0.134 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.134 0.032 DBMET00281 0.114 0.043 DBMET03601 | DBMET00281 | |
| 0.048 | 0.02 | 0.048 | Nerve growth factor antagonist | 0.042 0.03 DBMET00281 | ||
| 0.138 | 0.11 | 0.151 | Antipruritic | 0.151 0.093 DBMET00281 0.133 0.117 DBMET00743 0.145 0.1 DBMET03601 | DBMET00281 | |
| 0.093 | 0.065 | 0.093 | Phosphodiesterase 7B inhibitor | |||
| 0.085 | 0.059 | 0.438 | NMDA receptor antagonist | 0.291 0.007 DBMET00281 0.141 0.027 DBMET00743 0.438 0.004 DBMET03601 | DBMET03601 | |
| 0.04 | 0.015 | 0.043 | Potassium channel small-conductance Ca-activated activator | 0.043 0.013 DBMET00281 | DBMET00281 | |
| 0.048 | 0.022 | 0.052 | GABA B receptor antagonist | 0.052 0.018 DBMET00281 0.042 0.031 DBMET00743 0.045 0.026 DBMET03601 | DBMET00281 | |
| 0.05 | 0.025 | 0.05 | Glutamate (mGluR5) agonist | |||
| 0.084 | 0.06 | 0.118 | Antineoplastic alkaloid | 0.118 0.038 DBMET00743 0.091 0.054 DBMET03601 | DBMET00743 | |
| 0.082 | 0.058 | 0.082 | Caspase 7 inhibitor | |||
| 0.071 | 0.048 | 0.071 | HIV-1 reverse transcriptase inhibitor | 0.06 0.059 DBMET00743 | ||
| 0.092 | 0.069 | 0.105 | Bile acid receptor antagonist | 0.105 0.039 DBMET00743 0.089 0.076 DBMET03601 | DBMET00743 | |
| 0.034 | 0.012 | 0.034 | LFA antagonist | 0.025 0.024 DBMET00743 | ||
| 0.089 | 0.067 | 0.127 | Protein kinase C zeta inhibitor | 0.104 0.046 DBMET00281 0.107 0.043 DBMET00743 0.127 0.028 DBMET03601 | DBMET03601 | |
| 0.061 | 0.039 | 0.061 | Phosphodiesterase 1A inhibitor | 0.059 0.043 DBMET00281 | ||
| 0.15 | 0.131 | 0.239 | Focal adhesion kinase 2 inhibitor | 0.239 0.043 DBMET00281 0.171 0.099 DBMET03601 | DBMET00281 | |
| 0.153 | 0.134 | 0.194 | Aryl hydrocarbon receptor agonist | 0.194 0.106 DBMET00281 0.151 0.135 DBMET00743 0.192 0.107 DBMET03601 | DBMET00281 | |
| 0.153 | 0.134 | 0.154 | Histone acetyltransferase inhibitor | 0.154 0.133 DBMET00281 | DBMET00281 | |
| 0.226 | 0.207 | 0.226 | Analgesic | |||
| 0.151 | 0.134 | 0.151 | Potassium channel blocker | |||
| 0.168 | 0.152 | 0.22 | MAP-kinase-activated kinase 5 inhibitor | 0.22 0.082 DBMET00281 0.174 0.142 DBMET00743 0.217 0.085 DBMET03601 | DBMET00281 | |
| 0.103 | 0.087 | 0.103 | Acetylcholine muscarinic antagonist | 0.101 0.09 DBMET00743 | ||
| 0.076 | 0.061 | 0.076 | Histamine H1 receptor antagonist | |||
| 0.069 | 0.054 | 0.069 | 5 Hydroxytryptamine 1 antagonist | |||
| 0.087 | 0.074 | 0.113 | DNA directed RNA polymerase inhibitor | 0.113 0.043 DBMET00281 0.092 0.067 DBMET03601 | DBMET00281 | |
| 0.061 | 0.049 | 0.061 | 5 Hydroxytryptamine 1B antagonist | |||
| 0.109 | 0.099 | 0.109 | Sodium channel (voltage-gated) blocker | |||
| 0.041 | 0.031 | 0.053 | Dopamine D5 antagonist | 0.053 0.023 DBMET00743 | DBMET00743 | |
| 0.05 | 0.04 | 0.05 | Melanin-concentrating hormone receptor 1 antagonist | |||
| 0.027 | 0.019 | 0.027 | 11-Beta-hydroxysteroid dehydrogenase 2 inhibitor | |||
| 0.026 | 0.018 | 0.026 | Acid ceramidase inhibitor | |||
| 0.122 | 0.115 | 0.158 | Cyclin-dependent kinase 8 inhibitor | 0.158 0.072 DBMET00281 0.128 0.105 DBMET03601 | DBMET00281 | |
| 0.022 | 0.015 | 0.022 | Geranylgeranyltransferase inhibitor | |||
| 0.078 | 0.074 | 0.078 | T cell inhibitor | |||
| 0.059 | 0.055 | 0.059 | 5 Hydroxytryptamine 1A antagonist | |||
| 0.042 | 0.04 | 0.042 | Glutamate (mGluR group I) agonist | |||
| 0.04 | 0.039 | 0.04 | Potassium channel small-conductance Ca-activated blocker | |||
| 0.092 | 0.091 | 0.111 | GABA C receptor antagonist | 0.111 0.063 DBMET00281 0.108 0.067 DBMET03601 | DBMET00281 | |
| 0.014 | 0.013 | 0.015 | 4-Hydroxyphenylpyruvate dioxygenase inhibitor | 0.015 0.011 DBMET00743 | DBMET00743 | |
| 0.075 | 0.074 | 0.075 | GABA A receptor agonist | |||
| 0.055 | 0.056 | 0.092 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.071 0.027 DBMET00281 0.068 0.03 DBMET00743 0.092 0.013 DBMET03601 | DBMET03601 | |
| 0.065 | 0.066 | 0.066 | Glycine receptor agonist | 0.066 0.064 DBMET00281 | DBMET00281 | |
| 0.02 | 0.022 | 0.094 | NMDA receptor glycine site antagonist | 0.093 0.004 DBMET00281 0.094 0.004 DBMET03601 | DBMET03601 | |
| 0.052 | 0.055 | 0.126 | NMDA receptor glycine site agonist | 0.126 0.007 DBMET00281 0.109 0.013 DBMET03601 | DBMET00281 | |
| 0.157 | 0.161 | 0.221 | ErbB-1 antagonist | 0.219 0.071 DBMET00281 0.168 0.137 DBMET00743 0.221 0.07 DBMET03601 | DBMET03601 | |
| 0.012 | 0.015 | 0.016 | Egl nine homolog 1 inhibitor | 0.016 0.008 DBMET00743 | DBMET00743 | |
| 0.05 | 0.054 | 0.056 | 5 Hydroxytryptamine 7 agonist | 0.056 0.039 DBMET00281 0.051 0.049 DBMET03601 | DBMET00281 | |
| 0.051 | 0.057 | 0.079 | 5 Hydroxytryptamine 2A agonist | 0.079 0.028 DBMET00281 0.075 0.032 DBMET03601 | DBMET00281 | |
| 0.085 | 0.094 | 0.113 | Polo-like kinase-4 inhibitor | 0.113 0.063 DBMET00281 | DBMET00281 | |
| 0.127 | 0.137 | 0.137 | Heat shock protein 70 antagonist | 0.137 0.089 DBMET00743 | DBMET00743 | |
| 0.088 | 0.1 | 0.103 | Protein kinase C gamma inhibitor | 0.099 0.078 DBMET00281 0.093 0.091 DBMET00743 0.103 0.071 DBMET03601 | DBMET03601 | |
| 0.05 | 0.062 | 0.054 | Pregnane X receptor antagonist | 0.054 0.049 DBMET00281 0.053 0.052 DBMET03601 | DBMET00281 | |
| 0.078 | 0.09 | 0.143 | Creatine kinase inhibitor | 0.143 0.027 DBMET00743 0.13 0.034 DBMET03601 | DBMET00743 | |
| 0.041 | 0.053 | 0.058 | Potassium channel (ATP-sensitive) activator | 0.058 0.018 DBMET00281 0.044 0.043 DBMET03601 | DBMET00281 | |
| 0.042 | 0.055 | 0.06 | Potassium channel (Inward rectifier) activator | 0.06 0.019 DBMET00281 0.046 0.045 DBMET03601 | DBMET00281 | |
| 0.162 | 0.175 | 0.256 | Nitric-oxide synthase stimulant | 0.234 0.045 DBMET00281 0.181 0.127 DBMET00743 0.256 0.029 DBMET03601 | DBMET03601 | |
| 0.079 | 0.093 | 0.09 | Lanosterol 14 alpha demethylase inhibitor | 0.09 0.071 DBMET00281 0.085 0.082 DBMET03601 | DBMET00281 | |
| 0.083 | 0.098 | 0.087 | Phosphodiesterase 6D inhibitor | 0.087 0.084 DBMET00743 | DBMET00743 | |
| 0.02 | 0.036 | 0.026 | Protocollagen prolyl hydroxylase inhibitor | 0.026 0.022 DBMET00743 | DBMET00743 | |
| 0.129 | 0.145 | 0.141 | 3C-like protease (Human coronavirus) inhibitor | 0.141 0.118 DBMET00281 | DBMET00281 | |
| 0.073 | 0.092 | 0.091 | D-Ala-D-Ala ligase inhibitor | 0.091 0.043 DBMET00743 0.089 0.046 DBMET03601 | DBMET00743 | |
| 0.024 | 0.044 | 0.042 | Antidiuretic hormone antagonist | 0.042 0.026 DBMET00281 | DBMET00281 | |
| 0.022 | 0.043 | 0.073 | Kainate receptor 2 antagonist | 0.073 0.008 DBMET00281 0.05 0.016 DBMET03601 | DBMET00281 | |
| 0.021 | 0.042 | 0.027 | Liver X receptor alpha antagonist | 0.027 0.025 DBMET00743 | DBMET00743 | |
| 0.037 | 0.06 | 0.061 | Aldosterone antagonist | 0.061 0.019 DBMET00281 | DBMET00281 | |
| 0.087 | 0.112 | 0.106 | Nav1.5 sodium channel blocker | 0.106 0.075 DBMET00281 | DBMET00281 | |
| 0.066 | 0.092 | 0.109 | Opioid antagonist | 0.107 0.043 DBMET00743 0.109 0.042 DBMET03601 | DBMET03601 | |
| 0.015 | 0.041 | 0.025 | Vasopressin 1A antagonist | 0.025 0.023 DBMET00281 | DBMET00281 | |
| 0.034 | 0.061 | 0.056 | Glutamate (mGluR4) antagonist | 0.056 0.016 DBMET00281 0.044 0.029 DBMET03601 | DBMET00281 | |
| 0.03 | 0.058 | 0.045 | AMPA 4 receptor antagonist | 0.045 0.02 DBMET00281 0.044 0.02 DBMET03601 | DBMET00281 | |
| 0.012 | 0.041 | 0.071 | AMPA 1 receptor antagonist | 0.07 0.008 DBMET00281 0.071 0.008 DBMET03601 | DBMET03601 | |
| 0.046 | 0.08 | 0.117 | NMDA receptor agonist | 0.117 0.014 DBMET00281 0.102 0.019 DBMET03601 | DBMET00281 | |
| 0.024 | 0.061 | 0.054 | Glutamate (mGluR3) antagonist | 0.054 0.01 DBMET00281 0.05 0.013 DBMET03601 | DBMET00281 | |
| 0.14 | 0.179 | 0.169 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.169 0.11 DBMET00743 0.169 0.11 DBMET03601 | DBMET03601 | |
| 0.021 | 0.06 | 0.093 | NMDA receptor subunit 3A antagonist | 0.049 0.02 DBMET00281 0.034 0.031 DBMET00743 0.093 0.009 DBMET03601 | DBMET03601 | |
| 0.014 | 0.054 | 0.019 | Granulocyte colony stimulating factor receptor agonist | 0.019 0.011 DBMET00281 | DBMET00281 | |
| 0.047 | 0.087 | 0.089 | Prostaglandin-E synthase inhibitor | 0.089 0.033 DBMET00281 0.078 0.04 DBMET03601 | DBMET00281 | |
| 0.025 | 0.066 | 0.039 | Opioid kappa receptor agonist | 0.039 0.036 DBMET00743 | DBMET00743 | |
| 0.014 | 0.056 | 0.021 | Thymidine kinase (Herpes simplex virus 2) inhibitor | 0.021 0.014 DBMET00281 | DBMET00281 | |
| 0.089 | 0.131 | 0.112 | Ribosomal protein S6 kinase inhibitor | 0.112 0.1 DBMET00281 | DBMET00281 | |
| 0.041 | 0.086 | 0.068 | Dihydroorotate oxidase inhibitor | 0.063 0.025 DBMET00281 0.068 0.019 DBMET03601 | DBMET03601 | |
| 0.038 | 0.083 | 0.153 | NMDA 2C receptor antagonist | 0.121 0.01 DBMET00281 0.153 0.007 DBMET03601 | DBMET03601 | |
| 0.065 | 0.111 | 0.085 | Potassium channel activator | 0.085 0.068 DBMET00281 | DBMET00281 | |
| 0.043 | 0.091 | 0.073 | Heat shock protein 90 beta antagonist | 0.062 0.037 DBMET00743 0.073 0.026 DBMET03601 | DBMET03601 | |
| 0.031 | 0.08 | 0.056 | 5 Hydroxytryptamine 2 agonist | 0.056 0.031 DBMET00281 | DBMET00281 | |
| 0.028 | 0.076 | 0.052 | Opioid agonist | 0.051 0.039 DBMET00743 0.052 0.037 DBMET03601 | DBMET03601 | |
| 0.026 | 0.075 | 0.136 | NMDA receptor subunit 3B antagonist | 0.064 0.017 DBMET00281 0.039 0.037 DBMET00743 0.136 0.007 DBMET03601 | DBMET03601 | |
| 0.125 | 0.18 | 0.208 | Neurotrophic factor enhancer | 0.156 0.13 DBMET00281 0.176 0.102 DBMET00743 0.208 0.069 DBMET03601 | DBMET03601 | |
| 0.164 | 0.221 | 0.206 | Vasodilator, peripheral | 0.199 0.177 DBMET00281 0.206 0.17 DBMET03601 | DBMET03601 | |
| 0.037 | 0.096 | 0.053 | Fatty acid synthase inhibitor | 0.053 0.046 DBMET03601 | DBMET03601 | |
| 0.029 | 0.089 | 0.111 | Glutamate (mGluR1) antagonist | 0.111 0.013 DBMET00281 0.066 0.034 DBMET03601 | DBMET00281 | |
| 0.026 | 0.088 | 0.041 | 5 Hydroxytryptamine 2B agonist | 0.041 0.023 DBMET00281 | DBMET00281 | |
| 0.059 | 0.12 | 0.103 | Urease inhibitor | 0.103 0.063 DBMET03601 | DBMET03601 | |
| 0.041 | 0.106 | 0.168 | Cyclin B3 inhibitor | 0.168 0.01 DBMET00281 0.16 0.012 DBMET03601 | DBMET00281 | |
| 0.01 | 0.074 | 0.022 | Kainate receptor 4 antagonist | 0.022 0.02 DBMET00281 | DBMET00281 | |
| 0.005 | 0.07 | 0.022 | Kainate receptor 1 antagonist | 0.022 0.014 DBMET00281 | DBMET00281 | |
| 0.023 | 0.089 | 0.036 | Tryptophan 5 hydroxylase inhibitor | 0.036 0.025 DBMET00281 | DBMET00281 | |
| 0.01 | 0.078 | 0.028 | AMPA 3 receptor antagonist | 0.028 0.022 DBMET00281 | DBMET00281 | |
| 0.045 | 0.116 | 0.083 | Potassium channel large-conductance Ca-activated activator | 0.065 0.05 DBMET00743 0.083 0.033 DBMET03601 | DBMET03601 | |
| 0.057 | 0.129 | 0.089 | GABA B receptor agonist | 0.073 0.058 DBMET00281 0.089 0.027 DBMET03601 | DBMET03601 | |
| 0.062 | 0.135 | 0.094 | UDP-glucose 4-epimerase inhibitor | 0.086 0.079 DBMET00281 0.094 0.068 DBMET03601 | DBMET03601 | |
| 0.049 | 0.125 | 0.081 | Myeloperoxidase inhibitor | 0.081 0.064 DBMET03601 | DBMET03601 | |
| 0.094 | 0.171 | 0.148 | Hexokinase inhibitor | 0.126 0.11 DBMET00281 0.148 0.081 DBMET03601 | DBMET03601 | |
| 0.014 | 0.092 | 0.053 | Kainate receptor antagonist | 0.053 0.02 DBMET00281 0.046 0.024 DBMET03601 | DBMET00281 | |
| 0.052 | 0.131 | 0.083 | Opioid kappa receptor antagonist | 0.083 0.054 DBMET00743 0.078 0.06 DBMET03601 | DBMET00743 | |
| 0.007 | 0.088 | 0.032 | Dopamine autoreceptor agonist | 0.024 0.016 DBMET00281 0.032 0.012 DBMET03601 | DBMET03601 | |
| 0.065 | 0.149 | 0.117 | MAP kinase 13 inhibitor | 0.117 0.058 DBMET00281 | DBMET00281 | |
| 0.144 | 0.23 | 0.21 | Hypoxia-inducible factor 1 alpha inhibitor | 0.21 0.14 DBMET00743 | DBMET00743 | |
| 0.104 | 0.19 | 0.138 | MAP kinase 3 inhibitor | 0.138 0.089 DBMET00281 | DBMET00281 | |
| 0.098 | 0.185 | 0.134 | DNA methyltransferase I inhibitor | 0.134 0.124 DBMET03601 | DBMET03601 | |
| 0.017 | 0.107 | 0.113 | NMDA 2A receptor antagonist | 0.082 0.019 DBMET00281 0.113 0.01 DBMET03601 | DBMET03601 | |
| 0.019 | 0.11 | 0.039 | Estrogen-related receptor beta antagonist | 0.039 0.013 DBMET00743 0.035 0.017 DBMET03601 | DBMET00743 | |
| 0.065 | 0.157 | 0.186 | AMP-activated protein kinase stimulant | 0.154 0.026 DBMET00281 0.186 0.013 DBMET03601 | DBMET03601 | |
| 0.057 | 0.154 | 0.096 | GABA C receptor agonist | 0.096 0.071 DBMET00281 0.092 0.076 DBMET03601 | DBMET00281 | |
| 0.063 | 0.162 | 0.127 | MAP kinase 12 inhibitor | 0.127 0.061 DBMET00281 | DBMET00281 | |
| 0.063 | 0.168 | 0.079 | CC chemokine 5 receptor agonist | 0.079 0.068 DBMET03601 | DBMET03601 | |
| 0.132 | 0.24 | 0.22 | 12-Lipoxygenase inhibitor | 0.22 0.131 DBMET00743 0.2 0.151 DBMET03601 | DBMET00743 | |
| 0.114 | 0.222 | 0.181 | Neurotensin receptor agonist | 0.157 0.086 DBMET00281 0.139 0.132 DBMET00743 0.181 0.048 DBMET03601 | DBMET03601 | |
| 0.05 | 0.161 | 0.085 | HIV-1 integrase (Overall Integration) inhibitor | 0.085 0.071 DBMET03601 | DBMET03601 | |
| 0.061 | 0.173 | 0.079 | Estrogen-related receptor beta agonist | 0.079 0.072 DBMET00743 | DBMET00743 | |
| 0.079 | 0.201 | 0.108 | Interleukin 2 antagonist | 0.108 0.069 DBMET00281 | DBMET00281 | |
| 0.04 | 0.162 | 0.075 | Macrophage migration inhibitory factor inhibitor | 0.075 0.058 DBMET00743 0.07 0.067 DBMET03601 | DBMET00743 | |
| 0.089 | 0.213 | 0.131 | Dual specificity phosphatase inhibitor | 0.131 0.119 DBMET00743 | DBMET00743 | |
| 0.081 | 0.206 | 0.181 | Pyruvate kinase inhibitor | 0.181 0.092 DBMET03601 | DBMET03601 | |
| 0.021 | 0.149 | 0.206 | NMDA 2 receptor antagonist | 0.13 0.021 DBMET00281 0.206 0.009 DBMET03601 | DBMET03601 | |
| 0.025 | 0.156 | 0.066 | MAP kinase 11 inhibitor | 0.066 0.059 DBMET00281 | DBMET00281 | |
| 0.065 | 0.197 | 0.117 | Aldehyde dehydrogenase inhibitor | 0.117 0.074 DBMET03601 | DBMET03601 | |
| 0.009 | 0.143 | 0.034 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.034 0.026 DBMET00743 | DBMET00743 | |
| 0.035 | 0.17 | 0.069 | Glutamate (mGluR) antagonist | 0.069 0.062 DBMET00281 | DBMET00281 | |
| 0.092 | 0.23 | 0.138 | Interferon gamma antagonist | 0.138 0.096 DBMET03601 | DBMET03601 | |
| 0.036 | 0.18 | 0.07 | GABA aminotransferase inhibitor | 0.07 0.061 DBMET03601 | DBMET03601 | |
| 0.131 | 0.284 | 0.227 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.227 0.128 DBMET00281 0.211 0.145 DBMET03601 | DBMET00281 | |
| 0.132 | 0.286 | 0.293 | Alpha-glucosidase inhibitor | 0.222 0.204 DBMET00743 0.293 0.163 DBMET03601 | DBMET03601 | |
| 0.172 | 0.33 | 0.378 | Calcium channel L-type activator | 0.253 0.202 DBMET00281 0.317 0.143 DBMET00743 0.378 0.097 DBMET03601 | DBMET03601 | |
| 0.071 | 0.23 | 0.124 | Dual specificity phosphatase 3 inhibitor | 0.124 0.123 DBMET03601 | DBMET03601 | |
| 0.013 | 0.174 | 0.037 | Dopamine D5 agonist | 0.037 0.032 DBMET03601 | DBMET03601 | |
| 0.037 | 0.199 | 0.105 | Alcohol dehydrogenase inhibitor | 0.105 0.047 DBMET03601 | DBMET03601 | |
| 0.081 | 0.254 | 0.129 | Adenylate cyclase stimulant | 0.129 0.104 DBMET03601 | DBMET03601 | |
| 0.049 | 0.222 | 0.103 | Cyclooxygenase 1 inhibitor | 0.103 0.097 DBMET03601 | DBMET03601 | |
| 0.058 | 0.231 | 0.106 | DOPA decarboxylase inhibitor | 0.106 0.065 DBMET03601 | DBMET03601 | |
| 0.121 | 0.297 | 0.189 | Neuropeptide Y2 antagonist | 0.189 0.141 DBMET00281 0.185 0.149 DBMET03601 | DBMET00281 | |
| 0.109 | 0.287 | 0.271 | Transcription factor NF kappa B inhibitor | 0.201 0.168 DBMET00743 0.271 0.112 DBMET03601 | DBMET03601 | |
| 0.181 | 0.362 | 0.272 | Antiinflammatory | 0.272 0.243 DBMET00743 | DBMET00743 | |
| 0.048 | 0.23 | 0.092 | Carbonic anhydrase III inhibitor | 0.092 0.072 DBMET03601 | DBMET03601 | |
| 0.061 | 0.247 | 0.204 | Peroxidase inhibitor | 0.204 0.058 DBMET03601 | DBMET03601 | |
| 0.019 | 0.206 | 0.062 | Dopamine agonist | 0.062 0.05 DBMET03601 | DBMET03601 | |
| 0.046 | 0.237 | 0.134 | Amylase inhibitor | 0.134 0.072 DBMET03601 | DBMET03601 | |
| 0.056 | 0.247 | 0.098 | Interleukin 12 antagonist | 0.098 0.057 DBMET03601 | DBMET03601 | |
| 0.122 | 0.325 | 0.218 | Insulysin inhibitor | 0.202 0.154 DBMET00281 0.218 0.132 DBMET03601 | DBMET03601 | |
| 0.157 | 0.37 | 0.243 | MAP kinase kinase 6 inhibitor | 0.243 0.199 DBMET00281 | DBMET00281 | |
| 0.03 | 0.252 | 0.064 | Beta 3 adrenoreceptor antagonist | 0.064 0.045 DBMET03601 | DBMET03601 | |
| 0.006 | 0.233 | 0.052 | Dopamine D2 agonist | 0.052 0.026 DBMET03601 | DBMET03601 | |
| 0.04 | 0.269 | 0.125 | Beta glucuronidase inhibitor | 0.09 0.088 DBMET00281 0.125 0.041 DBMET03601 | DBMET03601 | |
| 0.091 | 0.321 | 0.212 | Death-associated protein kinase 2 inhibitor | 0.21 0.028 DBMET00281 0.212 0.027 DBMET03601 | DBMET03601 | |
| 0.127 | 0.367 | 0.286 | Interleukin 2 agonist | 0.247 0.121 DBMET00281 0.286 0.084 DBMET03601 | DBMET03601 | |
| 0.013 | 0.266 | 0.042 | Poly(ADP-ribose) polymerase inhibitor | 0.042 0.037 DBMET00281 | DBMET00281 | |
| 0.039 | 0.303 | 0.079 | MAP kinase kinase 7 inhibitor | 0.079 0.049 DBMET03601 | DBMET03601 | |
| 0.078 | 0.362 | 0.124 | Death-associated protein kinase 1 inhibitor | 0.124 0.098 DBMET00281 | DBMET00281 | |
| 0.03 | 0.335 | 0.133 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.133 0.09 DBMET00281 0.116 0.105 DBMET03601 | DBMET00281 | |
| 0.005 | 0.323 | 0.034 | Factor XI inhibitor | 0.034 0.023 DBMET00281 | DBMET00281 | |
| 0.064 | 0.384 | 0.137 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.136 0.103 DBMET00281 0.137 0.1 DBMET03601 | DBMET03601 | |
| 0.074 | 0.403 | 0.161 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.161 0.117 DBMET00281 0.15 0.132 DBMET03601 | DBMET00281 | |
| 0.009 | 0.358 | 0.065 | Cyclin B2 inhibitor | 0.063 0.028 DBMET00281 0.065 0.027 DBMET03601 | DBMET03601 | |
| 0.009 | 0.363 | 0.059 | NMDA 2B receptor antagonist | 0.059 0.032 DBMET03601 | DBMET03601 | |
| 0.007 | 0.368 | 0.043 | Factor XIa inhibitor | 0.043 0.026 DBMET00281 | DBMET00281 | |
| 0.059 | 0.422 | 0.168 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.168 0.121 DBMET00281 | DBMET00281 | |
| 0.02 | 0.393 | 0.059 | Beta 2 adrenoreceptor agonist | 0.059 0.055 DBMET03601 | DBMET03601 | |
| 0.01 | 0.385 | 0.064 | Cyclin B1 inhibitor | 0.063 0.04 DBMET00281 0.064 0.038 DBMET03601 | DBMET03601 | |
| 0.008 | 0.394 | 0.056 | Cyclin B inhibitor | 0.055 0.038 DBMET00281 0.056 0.037 DBMET03601 | DBMET03601 | |
| 0.012 | 0.59 | 0.11 | Estrogen receptor beta antagonist | 0.108 0.049 DBMET00743 0.11 0.046 DBMET03601 | DBMET03601 | |
| 0.014 | 0.647 | 0.12 | Estrogen antagonist | 0.117 0.061 DBMET00743 0.12 0.055 DBMET03601 | DBMET03601 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |